Overview

A Phase 2, Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Phase:
Phase 2
Details
Lead Sponsor:
Angion Biomedica Corp